TNYA Logo

Tenaya Therapeutics, Inc. (TNYA) 

NASDAQ
Market Cap
$132.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
31 of 960
Rank in Industry
26 of 550

Largest Insider Buys in Sector

TNYA Stock Price History Chart

TNYA Stock Performance

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart …

Insider Activity of Tenaya Therapeutics, Inc.

Over the last 12 months, insiders at Tenaya Therapeutics, Inc. have bought $20M and sold $252,746 worth of Tenaya Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Tenaya Therapeutics, Inc. have bought $27.92M and sold $123,975 worth of stock each year.

Highest buying activity among insiders over the last 12 months: COLUMN GROUP III GP, LP (10 percent owner) — $20M. GOEDDEL DAVID V () — $20M.

The last purchase of 2,222,222 shares for transaction amount of $10M was made by GOEDDEL DAVID V () on 2024‑02‑12.

List of Insider Buy and Sell Transactions, Tenaya Therapeutics, Inc.

2024-11-18SaleSVP, Accounting and Fin. Ops.
2,258
0.0029%
$2.12$4,787-2.83%
2024-08-16SaleChief Executive Officer
9,748
0.0131%
$2.89$28,216+1.92%
2024-08-16SaleChief Medical Officer
7,428
0.01%
$2.89$21,500+1.92%
2024-08-16SaleSVP, Accounting and Fin. Ops.
2,363
0.0032%
$2.89$6,8400.00%
2024-03-05SaleChief Scientific Officer
3,300
0.0044%
$7.00$23,101-49.71%
2024-02-20SaleChief Scientific Officer
6,569
0.0087%
$5.34$35,046-31.68%
2024-02-16SaleChief Scientific Officer
4,681
0.0064%
$5.86$27,431-42.88%
2024-02-16SaleChief Executive Officer
6,358
0.0087%
$5.86$37,258-42.88%
2024-02-16SaleChief Medical Officer
6,500
0.0088%
$5.86$38,090-42.88%
2024-02-16SaleChief Fin. and Bus. Officer
5,201
0.0071%
$5.86$30,478-42.88%
2024-02-12Purchase
2.22M
2.6767%
$4.50$10M-35.51%
2024-02-12Purchase10 percent owner
2.22M
2.6767%
$4.50$10M-35.51%
2023-08-29SaleChief Scientific Officer
7,243
0.0111%
$4.26$30,855-18.16%
2023-08-16SaleChief Scientific Officer
4,007
0.0059%
$3.81$15,267-4.43%
2023-08-16SaleChief Executive Officer
5,563
0.0083%
$3.81$21,195-4.43%
2023-08-16SaleChief Medical Officer
5,563
0.0083%
$3.81$21,195-4.43%
2023-08-16SaleChief Fin. and Bus. Officer
4,452
0.0066%
$3.81$16,962-4.43%
2023-03-10Purchase
6,779
0.0092%
$2.60$17,596+47.13%
2023-03-10Purchase10 percent owner
6,779
0.0092%
$2.60$17,596+47.13%
2023-02-08Purchase
1.5M
1.9331%
$2.60$3.9M+16.12%

Insider Historical Profitability

20.77%
GOEDDEL DAVID V
13599275
17.1664%
$1.6770+27.92%
COLUMN GROUP III GP, LP10 percent owner
13599275
17.1664%
$1.6770+27.92%
Casdin Elidirector
6078860
7.6733%
$1.6720<0.0001%
Casdin Partners Master Fund, L.P.10 percent owner
3224849
4.0707%
$1.6710<0.0001%
Srivastava Deepakdirector
372435
0.4701%
$1.6710+31.12%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Column Group Llc$49.16M11.979.4M0%+$037.33
Casdin Capital$35.21M8.576.73M+5.51%+$1.84M1.74
RA Capital Management, L.P.$30.1M7.335.76M+4.5%+$1.3M0.03
BlackRock$24.59M5.994.7M+24.14%+$4.78M<0.01
T. Rowe Price$17.5M4.263.35M-26.36%-$6.27M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.